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Abstract
Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific
neutralizing monoclonal antibody RG-1 protects against human papillomavirus type 16 (HPV16)
challenge. Here we explored the nature of the RG-1 epitope and its contribution to viral infectivity.
RG-1 bound equivalently HPV16 L2 residues 17-36 with or without an intact C22-C28 disulphide
bridge. HPV16 L2 mutations K20A, C22A, C22S, C28A, C28S, or P29A prevented RG-1 binding,
whereas Y19A, K23A or Q24A had no impact. Mutation of either C22 or C28 to alanine or serine
compromises HPV16 pseudoviral infectivity both in vitro and in the murine vaginal tract, but does
not impact pseudovirion assembly. Despite their lack of infectivity, HPV16 pseudovirions containing
C22S or C28S mutant L2 bind to cell surfaces, are taken up, and expose the 17-36 region on the
virion surface as for wild type HPV16 pseudovirions suggesting normal furin cleavage of L2.
Mutation of the second cysteine residue in Bovine papillomavirus type 1 (BPV1) L2 to serine (C25S)
dramatically reduced the infectivity of BPV1 pseudovirions. Surprisingly, in contrast to the double
mutation in HPV16 L2, the BPV1 L2 C19S, C25S double mutation reduced BPV1 pseudovirion
infectivity of 293TT cells by only half.
Findings
Papillomavirus infection requires cleavage of minor cap-
sid protein L2 by furin [1]. Mature virions in solution are
resistant to furin cleavage and RG-1 binding [2-4]. The
binding of virions to cell surfaces, presumably via heparan
sulfate proteoglycans [5], promotes furin cleavage of L2,
and this can occur on the cell surface. Furin cleavage trig-
gers a conformational change that improves the accessi-
bility of L2 on the capsid surface and its recognition by
RG-1 [4]. RG-1 recognizes L2 residues 17-36 [2], and vac-
cination with this peptide in the appropriate context trig-
gers high titers of neutralizing antibodies and protection
against experimental challenge with homologous as well
as heterologous virus types [6]. The cross-protective
nature of this L2 epitope is consistent with its high degree
of sequence conservation among diverse papillomavirus
genotypes, and may reflect evolutionary constraints due
to critical biological functions within this region [7].
Therefore, we sought to identify L2 residues critical to
papillomavirus biology by deletion and alanine scanning
mutagenesis within the epitope defined by RG-1. The role
of L2 in infection is conserved in diverse papillomavirus
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types [8], but here we focus upon HPV16 because it is
associated with a half of cervical cancer cases and the
majority of HPV+vaginal, vulval, penile, anal, and head
and neck cancers [9].
Sequences of the codon-modified HPV16 L2 gene within
the region encoding the RG-1 epitope were deleted to gen-
erate the Δ17-30 and Δ23-36 deletion mutants [10]. As
controls, two additional deletion mutants Δ353-362 and
Δ393-403 were prepared with similarly sized deletions
introduced at the C-terminus of HPV16 L2. The four dele-
tion mutants or wild type HPV16 L2 were co-transfected
into 293TT cells with an HPV16 L1 expression vector [10]
and the SEAP reporter plasmid [11,12]. Three days later
the cells were harvested and detergent lysates were treated
with benzonase to remove unencapsidated DNA. HPV16
pseudovirions were purified using standard protocols
([11,12] as detailed in http://home.ccr.cancer.gov/LCO).
By comparison with wild type HPV16 L2, the introduction
of these deletions within L2 had no significant impact
upon the yield of particles in the appropriate gradient
fraction, as demonstrated by L1 Western blot analysis.
Likewise, Western blot analysis of purified HPV16 pseu-
dovirions revealed similar levels of wild type and deletion
mutant HPV16 L2 were present, suggesting that none of
the small deletions within L2 adversely impacted L1/L2
co-assembly into particles. Extraction of benzonase-resist-
ant, and therefore presumably encapsidated [11], DNA
from the purified HPV16 pseudovirions and visualization
by agarose gel electrophoresis revealed that L2 wild type
and mutant particles contained similar levels of encapsi-
dated reporter plasmid, implying that none of these small
deletions within L2 prevented DNA encapsidation.
HPV16 pseudovirions prepared in the absence of L2 were
not infectious above 0.1% of those containing wild type
L2, as demonstrated by measuring the ability to deliver
the SEAP reporter plasmid to 293TT cells (Table 1).
HPV16 pseudovirions carrying the L2 Δ17-30 and Δ23-36
had no detectable activity (i.e. >0.1% of wild type),
whereas the C-terminal deletion mutants Δ353-362 and
Δ393-403 exhibited similar activity to wild type L2.
These findings suggested that the 17-36 region containing
the RG-1 epitope is critical to viral infection whereas resi-
dues 353-362 and 393-403 are not. Therefore we applied
alanine scanning mutagenesis to highly conserved amino
acids within the 17-36 region to identify the contributions
of individual residues to infection. Mutations Y19A,
K20A, C22A, K23A, Q24A, C28A, or P29A were intro-
duced into HPV16 L2. By comparison with wild type
HPV16 L2, the introduction of these point mutations
within L2 had no significant impact upon the yield of par-
ticles in the appropriate fraction, as demonstrated by L1
Western blot analysis (Table 1). Likewise, Western blot
analysis of purified HPV16 pseudovirions revealed similar
levels of wild type and point mutant HPV16 L2 were
present (Table 1), suggesting that none of the point muta-
tions within L2 adversely impacted L1/L2 co-assembly
into HPV16 pseudovirion particles. However, the RG-1
monoclonal antibody did not react with K20A, C22A,
C28A L2 by Western blot. Reaction with the P29A L2
mutant was weak, whereas the Y19A, K23A, and Q24A
mutant L2 proteins were bound by RG-1 similarly to the
wild type HPV16 L2 in Western blots. All of the L2 point
mutant pseudovirions exhibited a wild type level of infec-
tivity with the exception of the C22A and C28A mutants
that lacked infectious activity upon 293TT cells using
either a SEAP or GFP reporter (Table 1).
Since the thiol groups of cysteine residues 22 and 28
might be required for disulphide bridging or for hydrogen
bonding, we tested the impact of C22S and C28S muta-
tions upon both RG-1 binding and viral infectivity. Either
of the C22S and C28S mutations prevented the recogni-
tion of HPV16 L2 by RG-1 in a Western blot. Like the
C22A and C28A point mutants, HPV16 pseudovirions
containing single C22S or C28S point mutations were not
detectably infectious in vitro for 293TT cells using the
SEAP assay. These results are consistent with those
recently reported by Campos and Ozbun in 293TT cells
and the spontaneously immortalized human keratinocyte
cell line HaCaT [13]. Conversely, they differ from those of
Conway et al who describe a 3-4 log increase in infectivity
of HaCaT cells per encapsidated genome for L2 C22S or
C28S containing HPV16 virions produced in the raft cul-
ture system [14]. This observation may reflect a reduced
ability of the L2 C22S or C28S containing HPV16 particles
to protect the encapsidated genome from sonication and
benzonase treatment during measurement of encapsi-
dated viral genome, resulting in very high specific infectiv-
ities of mutant as compared to wild type virions [14].
Neither study tested the impact of these mutations upon
HPV16 infection of squamous epithelium [13,14].
A mouse model of HPV infection in the vaginal squamous
epithelium has recently been developed as an alternative
to tissue culture studies [5,15]. Therefore we explored the
infectivity of the HPV16 pseudovirions containing single
C22A or C28A point mutations as compared to wild type
L2 in the mouse vaginal challenge model. As for the in
vitro studies in human cell lines, HPV16 pseudovirions
containing single C22A or C28A point mutations were
dramatically less infectious than those containing wild
type L2 (p < 0.01, for both mutants versus w.t.), but were
not significantly different from each other (Figure 1).
It is possible that the point mutations of C22 or C28 affect
either cell surface binding or appropriate trafficking of vir-
ions during infection. Campos and Ozbun observed
indistinguishable cell surface binding and uptake intoVirology Journal 2009, 6:176 http://www.virologyj.com/content/6/1/176
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endosome/lysosomes co-incident with LAMP-1 at 8 h
post infection [13]. Similarly we observed no clear differ-
ences in binding and trafficking between the wild type
and the C22S or C28S mutant HPV16 pseudovirions as
viewed at 2 h, 6 h or 20 h post infection by immunofluo-
rescent staining of the virions with a rabbit polyclonal
antiserum raised to HPV16 L1 VLP (not shown).
Campos and Ozbun also demonstrated that residues C22
and C28 form an intramolecular disulphide bond in
HPV16 pseudovirions [13]. The presence of an L2 C22-
C28 disulphide bond in HPV16 pseudovirions was sur-
prising since the neutralizing monoclonal antibody RG-1
binds to reduced L2 in Western blot analysis [2]. Conway
et al observed that HPV16 and HPV18 pseudovirions are
resistant to neutralization by RG-1 early in raft culture
production process, but they become sensitive as the rafts
mature [14]. Since they also observe that the redox envi-
ronment within the rafts and susceptibility to RG-1 neu-
tralization changes over this period [16], it is possible that
the redox state of C22 and C28 of L2 impacts their recog-
nition by RG-1. Therefore we sought to determine
whether RG-1 also binds to the L2 C22-C28 disulphide
bonded epitope. To address this question we synthesized
a biotinylated HPV16 L2 13-31 cyclized peptide and
reduced peptide. The redox status of the cyclized and
reduced peptide was confirmed by mass spectrometry,
since the mass of the latter is 2Da greater. The RG-1 mon-
oclonal antibody and a rabbit polyclonal antibody to
HPV16 L2 17-36 peptide each reacted indistinguishably
Table 1: Assembly, infectivity and RG-1 antibody reactivity of pseudovirions carrying mutant L2
Mutation within HPV16 
L2
Infectivity of mutant 
HPV16 pseudovirion 
relative to w.t. L2
Co-assembly of L2 and 
encapsidation as for 
w.t.
RG-1 Mab Binding 
(WB)
% Binding of polyclonal 
17-36 antiserum 
(ELISA)
Δ17 - 30 >0.1% Yes No -
Δ23 - 36 >0.1% Yes No -
Δ353 - 362 100% Yes Yes -
Δ393 - 403 100% Yes Yes -
Y19A 100% Yes Yes -
K20A 100% Yes No 100%
C22A >0.1% Yes No 84%
C22S >0.1% Yes No 96%
K23A 100% Yes Yes -
Q24A 100% Yes Yes -
C28A >0.1% Yes No 74%
C28S >0.1% Yes No 72%
P29A 100% Yes Weak 100%
C22/28S >0.1% Yes - 120%
L1 alone >0.1% - - -
HPV16 pseudovirions were prepared using expression vectors for SEAP, HPV16 L1 and wild type L2 or the L2 deletion mutants or point mutants 
indicated. The preparations were treated with benzonase to remove unencapsidated DNA, and virions purified on an optiprep gradient. The 
purified virions were examined for L1 by Western blot (WB) with MAb885 antibody, or for L2 with RG-1 antibody or a full length HPV16L2-
specific polyclonal antibody, or for encapsidated DNA by agarose gel-electrophoresis after extraction. The infectivity of 2-fold serially diluted 
pseudovirions was examined by measuring SEAP activity of 293TT cells three days after treatment with different volumes of the pseudovirion 
preparations. Rabbit polyclonal antiserum to HPV16 L2 17-36 peptide was tested for binding to HPV16 pseudovirions containing mutant L2 versus 
wild type L2 in an ELISA. (-) not done.Virology Journal 2009, 6:176 http://www.virologyj.com/content/6/1/176
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with the cyclized and reduced HPV16 L2 13-31 peptide in
an ELISA (Figure 2). Therefore both RG-1 monoclonal
antibody and the rabbit polyclonal antibody to HPV16 L2
17-36 peptide are able to bind to the L2 C22-C28 disul-
phide bonded or reduced HPV16 L2. This suggests that
the differing sensitivity to RG-1 neutralization of HPV16
and HPV18 virions derived from 10- and 20-day organo-
typic raft cultures does not reflect a change in the redox
state of the C22 to C28 disulphide bridge [14,16].
Furin recognizes residues 9-12 of HPV16 L2 and this
cleavage removes 12 N-terminal amino acids from L2 and
renders residues 17-36 accessible on the capsid surface for
binding to RG-1 or the rabbit polyclonal antiserum to this
epitope [1,4]. This process of revealing the 17-36 epitope
Impact of L2 C22A and C28A point mutations upon vaginal infection of mice by HPV16 pseudovirions Figure 1
Impact of L2 C22A and C28A point mutations upon vaginal infection of mice by HPV16 pseudovirions. Mice (5/
group) were treated with Depo-provera 4 days prior to challenge and then microtrauma was produced in the vaginal epithe-
lium using a cytobrush [14]. The mice were then challenged intra-vaginally with equivalent doses, as determined by L1 concen-
tration, of HPV16 pseudovirions containing a luciferase reporter plasmid and wild type L2 or single C22A or C28A point 
mutations, in a carboxymethylcellulose gel [2]. Three days post-challenge, luciferin was introduced into the vaginal vault and as 
a surrogate of infection the production of light by luciferase was visualized using a Xenogen IVIS 200 instrument.
Binding of RG-1 antibody to disulphide hairpin of HPV16 L2 Figure 2
Binding of RG-1 antibody to disulphide hairpin of HPV16 L2. An HPV16 L2 13-31 cyclized peptide, purified to >99% 
homogeneity by HPLC, was completely reduced by the addition of 50 mM DTT and heating to 60°C. The redox state of the 
cyclized and reduced peptide was confirmed by mass spectrometry. The main neutral mass in the reduced sample was 
2208.13Da and was 2Da larger than the 2206.13Da mass of the cyclized peptide. These main masses correspond to the 
expected masses of biotinylated HPV16 L2 13-31 peptide without and with disulfide bonds, respectively. The same day that the 
mass spectrometry was performed, the peptides were used to coat a microtiter plate. The binding of dilutions of RG-1, or a 
rabbit polyclonal antibody raised against HPV16 L2 17-36 peptide fused to KLH [2], to the cyclized or reduced HPV16 L2 13-
31 peptide was then compared by ELISA (B) using peroxidase-linked anti-mouse or anti-rabbit IgG secondary antibodies 
respectively.Virology Journal 2009, 6:176 http://www.virologyj.com/content/6/1/176
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upon virions takes several hours after their binding to the
cell surface and is blocked by furin inhibitors or a subset
of neutralizing monoclonal antibodies to L1. We hypoth-
esized that the point mutations of L2 C22 or C28 to serine
blocked infection by preventing the display the 17-36
epitope on the virus surface. To address this hypothesis,
HPV16 pseudovirions containing L2 with wild type or
C22S or C28S mutations were bound to HeLa cells for one
hour, and then unattached virions were removed by wash-
ing and cells were incubated for an additional five hours
at 37°C. As expected, there was minimal exposure of the
RG-1 epitope after one hour, as determined by immun-
ofluorescent staining with the rabbit polyclonal antibody
to HPV16 L2 17-36 peptide (Figure 3). After the 5 h chase,
there was robust staining of wild type HPV16 pseudoviri-
ons with the rabbit polyclonal antibody to HPV16 L2 17-
36 peptide, consistent with the previously described con-
formational changes and furin cleavage to expose this
epitope [4]. Surprisingly, the staining of the cells exposed
to HPV16 pseudovirions containing L2 C22S or C28S
mutations was only marginally weaker than that of the
wild type particles (Figure 3). Similar findings were
observed when infecting HaCaT cells (not shown). This
likely reflects the slightly reduced (~30%) binding of
HPV16 L2 17-36 peptide antiserum to L2 C22S or C28S
(Table 1) rather than inefficient furin cleavage of the C22S
or C28S mutant L2 in HPV16 pseudovirions. Thus these
findings suggest that the C22 and C28 residues are not
required for exposure of this epitope during HPV16 infec-
tion.
Our findings indicate that the neutralizing epitope within
residues 17-36 contains cysteine residues that are critical
for HPV16 pseudovirion infection and for neutralization
by RG-1 [2]. These cysteine residues are not necessary for
the initial binding and uptake of the virus. They are also
not required for display of the 17-36 epitope on the virion
surface, and are thus presumably dispensable for furin
cleavage of L2 [1,4].
It is possible that these two cysteines, and potentially the
neighboring conserved residues, are critical for binding to
some cellular factor that mediates papillomavirus infec-
tion. However, mutation of L2 Y19A, K20A, K23A, Q24A,
or P29A had no significant impact upon infectivity. Alter-
natively the disulphide hairpin between C22 and C28
might hold this region of L2 in a particular conformation,
and that its reduction upon uptake acts as a molecular
switch that is critical for infection, acting at a step follow-
ing furin cleavage. Since such a mechanism might be com-
Impact of L2 C22A and C28A point mutations upon display of residues 17-36 on the capsid surface Figure 3
Impact of L2 C22A and C28A point mutations upon display of residues 17-36 on the capsid surface. HPV16 pseu-
dovirions containing L2 with wild type or C22S or C28S mutations were bound to the surface of HeLa cells for one hour at 
37°C. These cells were either fixed (1 h) or washed and chased at 37°C for five hours prior to fixation (6 h). The exposure of 
the HPV16 L2 17-36 epitope upon the virion surface was then determined by immunofluorescent staining with the rabbit poly-
clonal antibody to HPV16 L2 17-36 peptide, as previously described [1,4].Virology Journal 2009, 6:176 http://www.virologyj.com/content/6/1/176
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mon among papillomaviruses, we tested whether the
equivalent two cysteine residues are also critical for infec-
tion by a highly divergent papillomavirus type, bovine
papillomavirus type 1 (BPV1), which infects a different
host at a cutaneous site and induces typically benign
fibropapillomas. As observed for HPV16, the mutation of
second cysteine residue in L2 to serine (C25S) dramati-
cally reduced the infectivity of BPV1 pseudovirions pro-
duced in the 293TT cells and carrying the SEAP reporter to
<0.1% of wild type [11]. Surprisingly, in contrast to the
double mutation in HPV16 L2, the BPV1 L2 C19S, C25S
double mutation reduced BPV1 pseudovirion infectivity
of 293TT cells by only 50%. This latter finding suggests
that the contribution of the disulphide bond between
these two cysteine residues exerts subtle conformational
changes within L2 during virion assembly that impact
infectivity in diverse papillomavirus types. Further
research to address potential differences in capsid protein
conformation of HPV pseudovirions/quasivirions and
organotypic raft and wart-derived virions during particle
maturation is also warranted. Although it is unclear
exactly how the L2 17-36 region contributes to papilloma-
virus infectivity, it remains an intriguing target for the
development of broadly protective HPV vaccine [17].
Abbreviations
HPV: human papillomavirus; BPV: bovine papillomavi-
rus; SEAP: Secreted alkaline phosphatase; GFP: green flu-
orescent protein.
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